Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contrasting Reproductive and Early Life-History Strategies in Recently Diverged Octocoral Species (<i>Paramuricea</i> spp.).

Ecology and evolution·2026
Same author

Production of the Auger-electron emitter <sup>161</sup>Ho for nuclear medicine using proton beams.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2026
Same author

Hydroxyquinoline-functionalised aza-crown macrocycles for lanthanide coordination.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Targeted β<sup>-</sup>-Particle Plus Conversion and Auger-Electron Therapy with <sup>161</sup>Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

First positronium lifetime imaging with scandium-44 on a long axial field-of-view PET/CT.

Frontiers in nuclear medicine·2025
Same author

Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls.

EJNMMI research·2025

Related Experiment Video

Updated: Jun 9, 2025

Hyperspectral Imaging as a Tool to Study Optical Anisotropy in Lanthanide-Based Molecular Single Crystals
07:24

Hyperspectral Imaging as a Tool to Study Optical Anisotropy in Lanthanide-Based Molecular Single Crystals

Published on: April 14, 2020

17.0K

Terbium sisters: current development status and upscaling opportunities.

Anzhelika N Moiseeva1, Chiara Favaretto1,2, Zeynep Talip3

  • 1Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen PSI, Switzerland.

Frontiers in Nuclear Medicine
|October 28, 2024
PubMed
Summary

Terbium radionuclides show promise for nuclear medicine, particularly 161Tb for cancer therapy. However, challenges in production capacity and yield limit the clinical use of other terbium isotopes.

Keywords:
nuclear reactionsproduction capabilitiesradiolanthanidesterbiumtheragnostics

More Related Videos

High-resolution Thermal Micro-imaging Using Europium Chelate Luminescent Coatings
09:01

High-resolution Thermal Micro-imaging Using Europium Chelate Luminescent Coatings

Published on: April 16, 2017

7.7K
Spark Plasma Sintering Apparatus Used for the Formation of Strontium Titanate Bicrystals
11:17

Spark Plasma Sintering Apparatus Used for the Formation of Strontium Titanate Bicrystals

Published on: February 9, 2017

9.8K

Related Experiment Videos

Last Updated: Jun 9, 2025

Hyperspectral Imaging as a Tool to Study Optical Anisotropy in Lanthanide-Based Molecular Single Crystals
07:24

Hyperspectral Imaging as a Tool to Study Optical Anisotropy in Lanthanide-Based Molecular Single Crystals

Published on: April 14, 2020

17.0K
High-resolution Thermal Micro-imaging Using Europium Chelate Luminescent Coatings
09:01

High-resolution Thermal Micro-imaging Using Europium Chelate Luminescent Coatings

Published on: April 16, 2017

7.7K
Spark Plasma Sintering Apparatus Used for the Formation of Strontium Titanate Bicrystals
11:17

Spark Plasma Sintering Apparatus Used for the Formation of Strontium Titanate Bicrystals

Published on: February 9, 2017

9.8K

Area of Science:

  • Nuclear medicine
  • Radiochemistry
  • Medical physics

Background:

  • Terbium radionuclides (149, 152, 155, 161Tb) are gaining interest for cancer diagnosis and therapy.
  • 161Tb is a preferred candidate over 177Lu for radiotherapy and treating minimal residual disease.

Purpose of the Study:

  • To review recent advancements in the production and separation of terbium radioisotopes.
  • To evaluate the potential for scaling up production for nuclear medicine applications.

Main Methods:

  • Review of current literature on terbium radionuclide production.
  • Analysis of established and emerging production protocols.
  • Assessment of separation techniques for no-carrier-added terbium isotopes.

Main Results:

  • Only 161Tb currently has an established production protocol for no-carrier-added forms via neutron irradiation of 160Gd.
  • Production capacity and yield remain significant challenges for other terbium radioisotopes (149, 152, 155Tb).

Conclusions:

  • 161Tb is well-positioned for nuclear medicine applications.
  • Overcoming production and separation challenges is crucial for realizing the full potential of other terbium radioisotopes in clinical settings.